Download the GLP-1 Obesity Deal Trends Report for analysis on dealmaking, investment, and innovation in the obesity therapeutics market. Essential for pharma, biotech, and financial professionals in business development, licensing, and portfolio strategy.| Evaluate
Trusted commercial intelligence, consensus forecasts, news and analysis for pharma, biotech and medtech industry - Explore Evaluate| Evaluate
Discover how pharma and biotech are converging in a consumer-driven landscape. Learn about direct-to-patient models, carve-out deals, and why some biotechs are going solo. Get early access to insights from “Pharma v Biotech: New Rules?” and stay ahead of the curve.| Evaluate
Discover how biotech and Big Pharma are evolving under pressure. From China’s R&D surge to pricing reform, we reveal key market shifts that are reshaping the pharma landscape.| Evaluate
The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.| Evaluate
Master your pharma forecasting with epidemiology, patient-flow, and sales-based methodologies. Download the eBook for expert insights and best practices.| Evaluate
Discover how a clinical-stage biotech partnered with J+D Forecasting to transform its oncology forecasting—accelerating Phase III launch readiness, building internal capability, and enabling strategic pipeline decisions with Onco+.| Evaluate
This one-page guide highlights five expert tips tohelp you navigate the unique challenges of oncology forecasting withgreater confidence.| Evaluate
Key announcements and data from the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), with accompanying analyses.| Evaluate
Biotech industry insights. Discover the key factors for biotech commercialization success, including strategic planning, hiring, and funding.| Evaluate
Discover 3 key insights from our webinar on first to market advantage in the pharma industry. Learn how these findings can impact your portfolio strategy.| Evaluate
If you missed our dealmaking trends webinar, here are 3 things we learned about unpartnered assets, M&A and partnerships.| Evaluate
